-
-
The Cost of Attacking the Pharmaceutical Industry
Trump
Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
-
NIH Cuts and the Future of U.S. Biopharma
NIH
Trump's proposed NIH budget cuts, agency consolidations, and funding restrictions could reshape U.S. biomedical research, strain U.S.-China collaborations, and shift national priorities toward AI and space tech.
-
Trump's Presidency: Impact on the U.S. Biopharma Industry
FDA
Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
-
-
Tecovirimat Ineffective for Clade I Mpox in DRC Study
NIH
A recent NIH study in the Democratic Republic of the Congo found that tecovirimat does not improve clade I mpox lesion resolution. Despite this, mortality rates were lower than average. The study emphasizes the need for more research on effective treatments and vaccines for clade I mpox.
-
-
-
-
郸城县|
晋宁县|
仙居县|
汉寿县|
临沭县|
文成县|
前郭尔|
沅江市|
彰武县|
金昌市|
济宁市|
克什克腾旗|
淮阳县|
新平|
汉川市|
吕梁市|
广元市|
五大连池市|
科尔|
永泰县|
温泉县|
佳木斯市|
曲水县|
绍兴县|
平果县|
天祝|
金坛市|
娄底市|
宁强县|
南汇区|
南雄市|
鹤庆县|
新竹市|
凉城县|
平潭县|
阳谷县|
丰都县|
平利县|
玛沁县|
景谷|
深泽县|